METROEarly discontinuation of steroid treatment in negative FDG-PET/CT patients with idiopathic retroperitoneal fibrosis. A prospective multicentric study

Assistance Publique Hopitaux De Paris0 个研究点目标入组 41 人开始时间: 2024年6月20日最近更新: 2024年8月21日

试验速览

暂无简介。

•Patient over 18 years old, New onset or untreated relapsing of active idiopathic retroperitoneal fibrosis (IRF) defined by the association of: oRelated-disease symptoms (Appendix 17.2) or elevated CRP level (>20 mg/l) AND oRetroperitoneal peri-aortic mass that surrounds the abdominal vessels on CT-scan

•Secondary retroperitoneal fibrosis including drug-related retroperitoneal fibrosis, active infections (such as tuberculosis) or malignancies, systemic vasculitis (such as ANCA-associated vasculitis), Erdheim-Chester disease (Appendix 17.3), patients with IgG4 disease may be enrolled, •Inhaled glucocorticoids (except for patients with documented asthma),, •Any previous treatment with rituximab, methotrexate, alemtuzumab, cyclophosphamide, azathiorpine, mycophenolate mofetil, infliximab, adalimumab, etanercept within the past 3 months,, •Pregnancy or breastfeeding,, •Non-affiliation to a social security regime,, •Subject deprived of freedom, subject under a legal protective measure, •Refusal to participate, •Contraindication to perform FDG-PET/CT,, •Contraindication to perform CT scan with injection of contrast agent,, •Contraindication to treatment by prednisone, •Active infection,, •Acute or chronic liver disease that is deemed sufficiently severe to impair their ability to participate in the trial,, •Active or history of malignancy in last 5 years. Individuals with squamous cell or basal cell skin carcinomas and individuals with cervical carcinoma in situ may be enrolled if they have received curative surgical treatment,, •Serum creatinine level greater than 400 µmol/L that cannot be attributed to underlying IRF,, •Live vaccination received from 4 weeks before inclusion,

发起方